Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
Latest Information Update: 21 Nov 2025
At a glance
- Drugs AVB-114 (Primary)
- Indications Rectal fistula
- Focus Therapeutic Use
- Acronyms STOMP-II
- Sponsors Avobis Bio
Most Recent Events
- 29 Oct 2025 According to Avobis Bio LLC media release, results from this trial were at a plenary session of the American College of Gastroenterology's Annual Scientific Meeting. The trial results were accepted as a late-breaking abstract and presented by Dr David A Schwartz, a STOMP2 investigator, Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition, and Department of Medicine, and Director of the Inflammatory Bowel Disease Center at Vanderbilt University Medical Center.
- 03 Oct 2025 According to Avobis Bio LLC media release, data from this trial will be presented at the American College of Gastroenterology's 2025 Annual Scientific Meeting at Plenary Session 4B:IBD on Wednesday October 29, 2025
- 07 Aug 2025 According to Avobis Bio LLC media release, RMAT designation provides benefits including frequent FDA interactions and discussion of potential surrogate endpoints or accelerated approval.